We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LeMaitre Hits 52-Week High on Strong International Presence
Read MoreHide Full Article
Share price of Burlington, MA-based LeMaitre Vascular, Inc. (LMAT - Free Report) reached a new 52-week high of $21.20 on Sep 13, eventually closing a bit lower at $20.39.
Notably, this represents a promising one-year return of approximately 45%, much better than the S&P 500’s 7.5% over the same time frame.
Meanwhile, we note that LeMaitre holds a Zacks Rank #2 (Buy). The stock has a market cap of $389.9 million and an impressive long-term expected earnings growth rate of 15%.
LeMaitre’s strong international foothold is a significant catalyst in our view. Notably, the company has initiated its operations in the countries of Madrid, Toronto, Melbourne and Shanghai in the just-reported second-quarter of fiscal 2016. On this regard we note LeMaitre registered 22% growth in its international operations on a year-over-year basis in the quarter.
The current strength in LeMaitre’s market position is very encouraging, courtesy of its flagship XenoSure, which registered 36% year-over-year growth in the reported quarter. In fact, the company’s entire biologic portfolio holds considerable promise, which consists of the Omniflow graft and the recently acquired ProCol graft that have strengthened the company’s foothold in the market.
On this regard, a glimpse at the second-quarter results reveals an impressive quarter for LeMaitre. Notably, adjusted earnings of 14 cents per share comfortably beat the Zacks Consensus Estimate by 3 cents. However, revenues of nearly $22 million were in line with the consensus mark.
LeMaitre, with its set of innovative product line, is a prominent player in the huge and growing peripheral vascular market. This niche market is expected to grow at a CAGR of 6.8% and reach $3.4 billion by 2022 globally, as per GlobalData. Buoyed by such optimistic trends, the company is expected to enhance its growth trajectory in the long haul.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 inched up by a penny to 55 cents over the last 30 days. Similarly, fiscal 2017 estimates increased by a penny to 63 cents over the same time frame.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
LeMaitre Hits 52-Week High on Strong International Presence
Share price of Burlington, MA-based LeMaitre Vascular, Inc. (LMAT - Free Report) reached a new 52-week high of $21.20 on Sep 13, eventually closing a bit lower at $20.39.
Notably, this represents a promising one-year return of approximately 45%, much better than the S&P 500’s 7.5% over the same time frame.
Meanwhile, we note that LeMaitre holds a Zacks Rank #2 (Buy). The stock has a market cap of $389.9 million and an impressive long-term expected earnings growth rate of 15%.
LEMAITRE VASCLR Price and Consensus
LEMAITRE VASCLR Price and Consensus | LEMAITRE VASCLR Quote
Growth Catalysts
LeMaitre’s strong international foothold is a significant catalyst in our view. Notably, the company has initiated its operations in the countries of Madrid, Toronto, Melbourne and Shanghai in the just-reported second-quarter of fiscal 2016. On this regard we note LeMaitre registered 22% growth in its international operations on a year-over-year basis in the quarter.
The current strength in LeMaitre’s market position is very encouraging, courtesy of its flagship XenoSure, which registered 36% year-over-year growth in the reported quarter. In fact, the company’s entire biologic portfolio holds considerable promise, which consists of the Omniflow graft and the recently acquired ProCol graft that have strengthened the company’s foothold in the market.
On this regard, a glimpse at the second-quarter results reveals an impressive quarter for LeMaitre. Notably, adjusted earnings of 14 cents per share comfortably beat the Zacks Consensus Estimate by 3 cents. However, revenues of nearly $22 million were in line with the consensus mark.
LeMaitre, with its set of innovative product line, is a prominent player in the huge and growing peripheral vascular market. This niche market is expected to grow at a CAGR of 6.8% and reach $3.4 billion by 2022 globally, as per GlobalData. Buoyed by such optimistic trends, the company is expected to enhance its growth trajectory in the long haul.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 inched up by a penny to 55 cents over the last 30 days. Similarly, fiscal 2017 estimates increased by a penny to 63 cents over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broader medical sector include IDEXX Laboratories Inc. (IDXX - Free Report) , Masimo Corporation (MASI - Free Report) and Lantheus Holdings Inc. (LNTH - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>